Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test

After quietly plowing the arid cancer vaccine field for a decade, a low profile Swiss biotech is throwing itself in the ring as a player to watch in the frenetic race to extend the benefits of immunotherapies to solid tumors.